ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope

ShEEP 请求 CytoViva 3D 暗场高光谱显微镜

• 批准号: 9906462
• 负责人: Rajagopal Ramesh
• 金额: --
• 依托单位: OKLAHOMA CITY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2020-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9906462
• 关键词: 3-Dimensional; Acute; Alzheimer' s Disease; Antibodies; Area; Arthritis; Award; Bacteria; Bacterial Infections; Binding; Biological; Cancer Biology; Cancer Center; Cells; Chronic Disease; Cities; Communities; Computer software; Consumption; Core Facility; Diagnosis; Disease; Drug Delivery Systems; Drug Prescriptions; Equipment; Family member; Funding; Future; Grant; Health Sciences; Healthcare Systems; Hepatitis; Image; Imagery; In Vitro; Inflammatory Bowel Diseases; Institutes; Institution; Intravenous; K-Series Research Career Programs; Label; Lead; Leadership; Legal patent; Maintenance; Malignant Neoplasms; Measurement; Mediating; Metals; Microscope; Military Personnel; Monitor; Noise; Oklahoma; Optics; Oral; Organelles; Organism; Pain; Pancreatitis; Patients; Peer Review; Pharmaceutical Preparations; Phase I Clinical Trials; Post-Traumatic Stress Disorders; Process; Protocols documentation; Quality of life; Quantum Dots; Reproduction spores; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Role; Route; Sampling; Scientist; Sheep; Ships; Signal Transduction; Small Interfering RNA; Surveys; Symptoms; System; Technology; Therapeutic; Time; Tissues; Training; Treatment Failure; Treatment outcome; United States National Institutes of Health; Universities; Veterans; Virus; Virus Diseases; Walking; Woman; animal imaging; cancer clinical trial; cancer therapy; career; clinical translation; design; drug development; drug efficacy; experience; experimental study; flexibility; human disease; improved; ineffective therapies; instrument; instrumentation; intraperitoneal; men; nanomedicine; nanoparticle; off-patent; particle; pathogen; plasmid DNA; receptor; software systems; tool; trafficking

One of the challenges in areas of drug development and drug delivery for treating various human diseases is the lack of understanding of the inherent cellular barriers that restrict the drug efficacy. Another challenge encountered by researchers conducting intracellular trafficking of molecules and their localization in cellular organelles is in the use of fluorescent labels that distort the study results with negative influence of these labels on samples. Further, lack of availability of adequate instrumentation restricts investigators from conducting cutting-edge research at their own institute. As a result they have to ship their materials to institutions/universities which are time-consuming, expensive, and do not give the investigator to know the results quickly. Therefore, continuous expansion of research infrastructure by acquiring appropriate equipment’s will enhance research activities among research investigator and lead to new discoveries. To override some of these limitations, we are requesting funds to purchase the CytoViva 3D Enhanced Darkfield Hyperspectral Microscope for enhancing the research conducted by investigators at the Oklahoma City VA Health Care System. This system offers high signal-to-noise 3D enhanced darkfield optical hyperspectral imaging specifically designed for imaging of label free particles/molecules in label-free or fluorescently labeled live cells and ex-vivo tissue matrices. The unique patented technology of the microscope allows the visualization and monitoring of particles, drugs, biologics, and cells in solution and in translucent matrices (cells, tissues, organisms). Thus, studies investigating binding of material (drug, nanoparticle, cell- particle interaction, antibody binding to cell), receptor-mediated binding and entry into cells (nanoparticles, quantum-dots, virus, bacteria, metals, antibodies) and intracellular localization and trafficking (siRNA, plasmid DNA, nanoparticles, virus, bacteria, spores) via various intracellular organelles can be determined in vitro and in ex-vivo tissue explants with label-free imaging and capture images. The system with the requisite computer software system provides quantitative spectral analysis of biological and non-biological materials imaged. The protocols can be automated giving the user to ‘walk-away’ from the instrument, and perform other experiments. Most importantly, neither the Oklahoma City VA Health Care System nor the affiliated University of Oklahoma Health Sciences Center (OUHSC) has such an instrument that enables high precision analysis of label-free materials in cells or ex-vivo tissues. Therefore, this is a truly unique and valuable resource justifying it purchase as a resource for investigators to conduct existing and new areas of research at the Oklahoma City VA Health Care System. Availability of this equipment will enhance ongoing studies and establish new areas of research benefitting the men and women serving the military and veterans. The equipment will be used by six-major users and a number of future VA users who have six VA Merit grants funded, three senior career scientist awards, and one career development award funded.

治疗各种人类疾病的药物开发和药物输送领域的挑战之一 是对限制药物疗效的固有细胞屏障缺乏了解。另一个挑战 研究人员在进行细胞内分子运输及其在细胞内定位时遇到的问题 细胞器中使用的荧光标记扭曲了研究结果，对这些标记产生了负面影响 在样品上。此外，缺乏适当的仪器设备限制了调查人员进行 在他们自己的研究所进行尖端研究。因此，他们不得不将他们的材料运往 机构/大学既耗时又昂贵，而且不能让调查人员了解 很快就能见效。因此，通过收购适当的研究基础设施，不断扩大研究基础设施 这些设备将加强研究人员的研究活动，并带来新的发现。 为了克服其中的一些限制，我们正在申请资金购买Cytoviva 3D增强版 用于加强俄克拉荷马大学研究人员研究的暗场高光谱显微镜 市退伍军人医疗保健系统。该系统提供高信噪比3D增强暗场光学 高光谱成像专为无标记或无标记的无标记粒子/分子成像而设计 荧光标记的活细胞和体外组织基质。显微镜独有的专利技术 允许可视化和监控溶液中和半透明中的颗粒、药物、生物制品和细胞 基质(细胞、组织、生物体)。因此，研究材料(药物、纳米颗粒、细胞--)的结合 颗粒相互作用、抗体与细胞的结合)、受体介导的结合和进入细胞(纳米颗粒， 量子点、病毒、细菌、金属、抗体)和细胞内定位和运输(siRNA、质粒 DNA、纳米粒子、病毒、细菌、孢子)通过各种细胞内细胞器在体外和 在体外组织外植体中进行无标记成像和捕获图像。配备必备计算机的系统 软件系统提供生物和非生物材料成像的定量光谱分析。这个 协议可以自动进行，让用户可以“离开”仪器，并进行其他实验。 最重要的是，无论是俄克拉荷马城退伍军人医疗保健系统还是俄克拉何马州附属大学 俄克拉荷马州健康科学中心(OUHSC)就有这样一种仪器，可以实现高精度 细胞或体外组织中无标记物质的分析。因此，这是一个真正独特和有价值的 将其作为调查人员进行现有研究和新领域研究的资源 俄克拉荷马城退伍军人医疗保健系统。这种设备的提供将加强正在进行的研究和 建立有益于军人和退伍军人的新的研究领域。 该设备将由六个主要用户和一些具有六个VA优点的未来VA用户使用 拨款、3个高级职业科学家奖和1个职业发展奖。